A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate^*

References

• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208–18
   PubMed Web of Science ®Google Scholar
• Ritz E. The clinical management of hyperphosphatemia. J Nephrol 2005;18:221–8
   PubMed Web of Science ®Google Scholar
• Kumar R. The metabolism and mechanism of action of 1,25-dihydroxyvitamin D3. Kidney Int 1986;30:793–803
   PubMed Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. New Engl J Med 2000;342: 1478–83
   PubMed Web of Science ®Google Scholar
• Block GA. Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients. Clin Nephrol 2000;54:318–24
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005;68:429–36
   PubMed Web of Science ®Google Scholar
• Anon. USRDS 2004 annual data report. Am J Kidney Dis 2005;45:8–280
   Google Scholar
• Anon. K/DOQI Guidelines 2003. Am J Kidney Dis 2003;42:S1–201
   PubMedGoogle Scholar
• Goodman WG, Duarte ME. Aluminum: effects on bone and role in the pathogenesis of renal osteodystrophy. Miner Electrolyte Metabol 1991;17:221–32
   PubMedGoogle Scholar
• McGonigle RJ, Parsons V. Aluminium-induced anaemia in haemodialysis patients. Nephron 1985;39:1–9
   PubMedGoogle Scholar
• Rob PM, Niederstadt C, Reusche E. Dementia in patients under going long-term dialysis: aetiology, differential diagnoses, epidemi ology and management. CNS Drugs 2001;15:691–9
   Google Scholar
• Sprague SM. The role of the bone biopsy in the diagnosis of renal osteodystrophy. Semin Dial 2000;13:152–5
   PubMed Web of Science ®Google Scholar
• Chertow GM, Raggi P, Chasan-Taber S, et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1489–96
   PubMed Web of Science ®Google Scholar
• Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone [The RenaGel Study Group]. Kidney Int 1999;55:299–307
   Google Scholar
• Coburn JW, Hartenbower DL, Massry SG. Intestinal absorption of calcium and the effect of renal insufficiency. Kidney Int 1973;4:96–104
   Google Scholar
• Hou SH, Zhao J, Ellman CF, et al. Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 1991;18:217–24
   PubMed Web of Science ®Google Scholar
• Winchester JF, Rotellar C, Goggins M, et al. Calcium and phosphate balance in dialysis patients. Kidney Int Suppl 1993;41:S174–S178
   PubMedGoogle Scholar
• Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014–21
   PubMed Web of Science ®Google Scholar
• London GM, Marchais SJ, Guerin AP, Metivier F. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005;14:525–31
   PubMed Web of Science ®Google Scholar
• Swearingen RA, Chen X, Petersen JS, et al. Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography. J Pharm Biomed Anal 2002;29:195–201
   PubMed Web of Science ®Google Scholar
• Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implica tions. Kidney Int Suppl 2004;S39–S45
   Google Scholar
• Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65:1914–26
   PubMed Web of Science ®Google Scholar
• Sonikian MA, Pani IT, Iliopoulos AN, et al. Metabolic acidosis aggravation and hyperkalemia in hemodialysis patients treated by sevelamer hydrochloride. Renal Fail 2005;27:143–7
   PubMed Web of Science ®Google Scholar
• Braunlin W, Zhorov E, Guo A, et al. Bile acid binding to sevelamer HCl. Kidney Int 2002;62:611–9
   PubMed Web of Science ®Google Scholar
• Autissier V, Damment SJP, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci 2007;96:2818–27
   Google Scholar
• Behets GJ, Verberckmoes SC, D’Haese PC, De Broe ME. Lanthanum carbonate: a new phosphate binder. Curr Opin Nephrol Hypertens 2004;13:403–9
   PubMed Web of Science ®Google Scholar
• Albaaj F, Hutchison AJ. Lanthanum carbonate (Fosrenol®): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients. Int J Clin Pract 2005;59:1091–6
   PubMed Web of Science ®Google Scholar
• Damment SJP, Totten W. The pharmacology of a new phosphate binder, lanthanum carbonate. Nephrol Dial Transplant 2003;18:683
   Google Scholar
• Locatelli F, D’Amico M, Pontoriero G. Lanthanum carbonate (Shire). IDrugs 2003;6:688–95
   PubMed Web of Science ®Google Scholar
• Hutchison AJ. Improving phosphate-binder therapy as a way forward. Nephrol Dial Transplant 2004;19:i19–i24
   PubMed Web of Science ®Google Scholar
• Curtin RB, Svarstad BL, Keller TH. Hemodialysis patients’ noncompliance with oral medications. ANNA J 1999;26:307–16
   Google Scholar
• Tomasello S, Dhupar S, Sherman RA. Phosphate binders, K/ DOQI guidelines, and compliance: the unfortunate reality. Dial Transplant 2004;33:236–40
   Google Scholar
• Anon. PhosLo® (calcium acetate). Full prescribing information, Nabi Biopharmaceuticals, Boca Raton (FL), 2005
   Google Scholar
• Anon. Renagel® (sevelamer hydrochloride). Full prescribing information, Genzyme Corporation, Cambridge (MA), 2005
   Google Scholar
• Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999;33:694–701
   PubMed Web of Science ®Google Scholar
• Anon. Fosrenol® (lanthanum carbonate). Full prescribing information, Shire US Inc, Wayne (PA), 2005
   Google Scholar
• Loghman-Adham M. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 2003;9:155–71
   PubMed Web of Science ®Google Scholar
• Matzke GR, St Peter WL, Comstock TJ, Foote EF. Nephrology pharmaceutical care preceptorship: a programmatic and clinical outcomes assessment. Ann Pharmacother 2000;34:593–9
   PubMed Web of Science ®Google Scholar
• Bleyer AJ. Phosphate binder usage in kidney failure patients. Exp Opin Pharmacother 2003;4:941–7
   PubMed Web of Science ®Google Scholar
• Cleary DJ, Matzke GR, Alexander AC, Joy MS. Medication knowledge and compliance among patients receiving long-term dialysis. Am J Health Syst Pharm 1995;52:1895–900
   PubMed Web of Science ®Google Scholar
• Mehrotra R. Preference and satisfaction with reformulated higher-dosage strength lanthanum carbonate. J Am Soc Nephrol 2006;17:356A
   Google Scholar
• Mehrotra R. Efficacy and safety of higher-strength lanthanum carbonate. J Am Soc Nephrol 2006;17:356A
   Google Scholar
• Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005;20:1653–61
   PubMed Web of Science ®Google Scholar
• Braun J, Asmus HG, Holzer H, et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate – phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004;62:104–15
   PubMed Web of Science ®Google Scholar
• Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Med J 2004;25:785–91
   Google Scholar
• Hutchison AJ, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005;100:8–19
   PubMed Web of Science ®Google Scholar
• Finn WF, Joy MS. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin 2005;21:657–64
   PubMed Web of Science ®Google Scholar
• Ribeiro S, Ramos A, Brandao A, et al. Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998;13:2037–40
   PubMed Web of Science ®Google Scholar
• Rostand SG, Sanders C, Kirk KA, et al. Myocardial calcification and cardiac dysfunction in chronic renal failure. Am J Med 1988;85:651–7
   PubMed Web of Science ®Google Scholar
• Lim VS, Yarasheski KE, Flanigan MJ. The effect of uraemia, acidosis, and dialysis treatment on protein metabolism: a longitudinal leucine kinetic study. Nephrol Dial Transplant 1998;13:1723–30
   Google Scholar
• Mak RH. Effect of metabolic acidosis on insulin action and secretion in uremia. Kidney Int 1998;54:603–7
   PubMed Web of Science ®Google Scholar
• Bushinsky DA, Smith SB, Gavrilov KL, et al. Chronic acidosis-induced alteration in bone bicarbonate and phosphate. Am J Physiol Renal Physiol 2003;285:F532–F539
   PubMed Web of Science ®Google Scholar
• Graham KA, Hoenich NA, Tarbit M, et al. Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. J Am Soc Nephrol 1997;8:627–31
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Maes B, Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 2006;102:c61–c71
   PubMedGoogle Scholar
• Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003;42:96–107
   PubMed Web of Science ®Google Scholar
• D’Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003;63:S73–S78
   Google Scholar
• Altmann P, Barnett ME, Finn WF. Cognitive function in stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int 2007;71: 252–9
   Google Scholar
• Pratt R. Evidence for the long-term safety and tolerability of lanthanum carbonate. J Am Soc Nephrol 2005;16:765A
   Google Scholar
• Pennick M, Dennis K, Damment SJ. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacol 2006;46:738–46
   Google Scholar
• Lacour B, Lucas A, Auchere D, et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005;67:1062–9
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005;68:2809–13
   PubMed Web of Science ®Google Scholar
• Anon. RED BOOKTM [database on CD-Rom]. Greenwood Village [CO]: Thomson Micromedex; 2007
   Google Scholar